The ENT devices are used in the diagnosis and treatment of ear, nose, and throat diseases. The main types of ENT devices are hearing aid devices and equipment, hearing diagnostic devices and equipment, ENT surgical devices and equipment, hearing implants, voice prosthesis devices and equipment, and nasal splints. A hearing aid device is an electronic device that is worn in or behind the ear. It makes sounds louder so that a person with hearing loss can listen, communicate, and participate fully in daily activities. The type of expenditure is public and private. The products used are instruments/equipment and disposables. The various end-users are hospitals and clinics, diagnostic laboratories, and others. The ENT devices market research report is one of a series of new reports from The Business Research Company that provides ENT devices market statistics, including ENT devices industry global market size, regional shares, competitors with an ENT devices market share, detailed ENT devices market segments, market trends and opportunities, and any further data you may need to thrive in the ENT devices industry. This ENT devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global ent devices market grew from $30.21 billion in 2022 to $32.98 billion in 2023 at a compound annual growth rate (CAGR) of 9.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The ent devices market is expected to grow to $45.04 billion in 2027 at a CAGR of 8.1%. Many governments across the world have introduced new healthcare acts and continuously increased healthcare spending. Healthcare coverage and expenditure also increased significantly. In 2021, the Indian government launched Ayushman Bharat PradhanMantri Jan ArogyaYojana (AB-PMJAY) is providing health assurance cover of up to ?5 Lakh per year per family for secondary and tertiary healthcare hospitalizations. Favourable government decisions and increased healthcare spending increased the demand for healthcare services and this drove the demand for ENT devices during this period. Interest rates globally are forecasted to rise in most of the developing and developed economies during the forecast period; this is expected to limit new investments in the market. Most countries across the world are raising interest rates to control inflation and also to limit the flow of capital out of the country. This is likely to affect new investments in terms of expansion, research, and development of new products. For instance, the US interest rates are expected to rise to 3.5% by 2021. These factors are expected to have a negative impact on the market as borrowing money becomes expensive, thereby affecting the market growth. ENT device manufacturers are investing in technologies to develop user-friendly and non-invasive equipment. They are continuously investing funds and resources into R&D to increase the scope of their devices. For instance, Intersect ENT developed Propel Mometasone Furoate Implant (PMFI) to treat chronic sinusitis. It is a bio-absorbable steroid that is placed directly into the sinus mucosa. It controls the release of drugs and dissolves over time. In another breakthrough in sinusitis treatment, SinuSys Corporation received FDA approval for its Vent-Os Sinus Dilation device. It is a small, low-pressure insert that is designed to gently open the sinus ostia and use the body’s natural mucosal fluids to expand the device. Major companies in the ENT devices market include Sonova Holdings AG, William Demant Holdings A/S, Medtronic Inc., GN Store Nord A/S, Cochlear Limited, Olympus Corporation, Stryker Corporation, Karl Storz SE & Co KG, Merck & Co, and Smith & Nephew plc. Asia-Pacific was the largest region in the global ENT devices market in 2022. North America was the second largest region in the global ENT devices market. Africa. was the smallest region in the global ENT devices market. The regions covered in the ENT devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the ENT devices market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The ENT devices market consists of sales of instruments such as Pure tone and impedance audiometers, BERA and OAE screening machines, nerve stimulators, and high-end microdrill that are used for diagnosis and treatment of ENT diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global ent devices market is segmented - 1) By Type: Hearing Aid Devices And Equipment, Hearing Diagnostic Devices And Equipment, ENT Surgical Devices And Equipment, Hearing Implants, Voice Prosthesis Devices And Equipment, Nasal Splints 2) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables

Nasal splints are devices designed to fit inside or on the nose to provide support after nasal surgery. Nasal splints include intranasal splints and external nasal splints. Intranasal splints are placed into the nose and are used to maintain septal stability and prevent intranasal adhesions following septal surgery. External nasal splints are placed on the outer part of the nose and used to prevent the nose from moving following rhinoplasty or nasal contouring procedures. The main types of nasal splints market are malleable nasal splints, airway nasal splints, and bivalve nasal splints. The bivalve nasal splints are designed to provide septal support and reduce or prevent adhesions between the septum and lateral nasal wall following surgery. The various applications involved are plastic surgery, rhinological operations, ENT surgery, and others. The various end-users are hospitals and clinics, home care, research centres, and others. The nasal splints market research report is one of a series of new reports from The Business Research Company that provides nasal splints market statistics, including nasal splints industry global market size, regional shares, competitors with a nasal splints market share, detailed nasal splints market segments, market trends and opportunities, and any further data you may need to thrive in the nasal splints industry. This nasal splints market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global nasal splints market size will grow from $6.25 billion in 2022 to $6.9 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The nasal splints market size is expected to grow to $9.68 billion in 2027 at a CAGR of 8.8%. Rhinoplasty is one of the most commonly performed reconstructive cosmetic surgery across the globe and Rhinoplasty accounted for 62% of the procedures performed on women and 79% of procedures performed on men in 2021. As part of the post-operative procedure, intranasal splints are used to promote hemostasis, structural support and minimize scar formation. Therefore, owing to the rising numbers of rhinoplasty surgery and the use of nasal splints for post-operative care, the market for nasal splints is forecasted to grow. The nasal splints market was limited by a shortage of skilled surgeons and other professionals in most developed and developing countries. Equipment fabrication and integration require specialized skillsets relating to nasal surgeries, and electronics and software. According to a survey conducted by the International Society of Aesthetic Plastic Surgery (ISAPS), in the Middle Eastern countries such as Iran, there were only 238 surgeons to perform 37,423 nose jobs. The specialized skillsets relating to nasal surgeries are available to a limited number of organizations, most of which are located in the USA and Europe. This shortage of skilled surgeons and other professionals is a significant deterrent to the growth of the market. Nasal splints made from biodegradable materials are gaining popularity in the industry, as they do not require surgical removal after implantation. The biodegradable materials in nasal splints include plant-based and bioresorbable materials. They help in controlling bleeding after surgery or nasal trauma, eliminating the need for painful nasal packing removal for patients, and act as an adjunct to aid in the natural healing process. For instance, Smith & Nephew offers a dissolvable nasal splint Nasastent composed of plant-based carboxymethyl cellulose that helps to support the soft nasal tissue and provides pressure to prevent bleeding. This implant eventually converts into a hydro colloidal gel after absorbing nasal fluid and drains from the patient naturally. Some of the other companies offering biodegradable nasal splints are Hemostasis LLC., Medtronic and others. As per the US FDA, nasal splints are classified as Class I medical devices that are exempted from premarket notification. However, nasal splint manufacturers must register their establishment and list the generic category or classification name. Major players in the nasal splints market are Boston Medical Products Inc., Innovia Medical LLC., Medtronic PLC., Olympus Corporation, Smith & Nephew, DTR Medical, Mentor Worldwide LLC., Network Medical Products, Summit Medical Group, and Surgiform Technologies LLC. Asia-Pacific was the largest region in global nasal splints market in 2022. North America was the second-largest region in the nasal splints market. The regions covered in the global nasal splints market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the nasal splints market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The nasal splints market consists of sales of instruments such as malleable nasal splints, airway nasal splints, and bivalve nasal splints. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global nasal splints market is segmented - 1)By Type: Malleable Nasal Splints, Airway Nasal Splints, Bivalve Nasal Splints, 2) By End User: Hospitals & Clinics, Homecare, Research Centers, Other End Users 3) By Application: Plastic Surgery, Rhinological operations, ENT-Surgery, Other Applications 4) By Route of Administration: Intranasal Segment, Extranasal Segment

The cold and cough preparations refer to the medications that are used to treat cold and cough. The drugs for the treatment of cold and cough act on the receptors to which the virus causing the infection gets attached, by antagonizing the action of the receptors and killing the viral infection, thereby reducing congestion by lysing the mucus and dilating the bronchioles constricted by the mucus deposition. The main types of drugs in cold and cough preparations are antihistamines, expectorants, bronchodilators, decongestants, antibiotics, and others. Antihistamines are drugs or other compounds that block the physiological effects of histamine and are used to treat allergies in particular. The different types include bronchodilators, anticholinergic, and pulmonary antihypertensives. The several dosage types include oral syrups, tablets or pills, nasal drops, lozenges, and others and are distributed through various channels such as hospital pharmacies, retail pharmacies, and drug stores. The cold and cough preparations market research report is one of a series of new reports from The Business Research Company that provides cold and cough preparations market statistics, including cold and cough preparations industry global market size, regional shares, competitors with a cold and cough preparations market share, detailed cold and cough preparations market segments, market trends and opportunities, and any further data you may need to thrive in the cold and cough preparations industry. This cold and cough preparations market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cough and cold preparations market size will grow from $66.75 billion in 2022 to $70.37 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global cough and cold preparations market size is expected to grow to $84.02 billion in 2027 at a CAGR of 4.5%. The rising incidence of allergies is expected to fuel the growth of the cough and cold preparations market in the forecast period. There are many respiratory allergies such as pollen, dust, mold, and pet allergies; these allergies are caused due to contaminated outdoor and indoor air. Cough and cold preparations are consumed for treating allergies, which cause cough and cause issues in the respiratory tract. For instance, according to the European Academy of Allergy and Clinical Immunology, a non-profit organization for European clinicians, researchers, and allied health professionals, by 2025, 1 in every 3 people in the European Union is expected to be affected by allergies. Thus, the increase in the incidence of respiratory allergies will bolster the demand for cough and cold preparations, positively affecting the growth of the market. Threat from substitute products such as generic and counterfeit drugs is significantly restraining the global cold and cough preparations market. Pharmaceutical companies invest a large sum of money in the drug development process. Once a drug candidate is developed and approved by the regulatory authorities, companies patent their inventions to protect their intellectual property. During the patency period, the company holding the patent holds exclusivity for manufacturing and distribution. Post expiration of patency, generic versions of the drugs is manufactured by other companies. The prices of the generics are very low in comparison to the original brand of the drug. According to an article by Alpha InvesCo., a new FDA-approved blockbuster drug that netted $100 million a year in profit during its patent protection duration could become one that earns only $1 million a year in profit overnight after losing its patent. Additionally, there is a major international problem with counterfeit drugs. The best of these counterfeits duplicates a real drug’s formula and sells it at a lower price, which hurts pharmaceutical companies' profits. Moreover, counterfeits made with low-grade materials can destroy the reputations of legitimate products, thus affecting the growth of the market. Advancements in technologies are driving the global pharmaceutical sector including cold and cough preparations. According to a global life sciences report by Deloitte, the adoption of AI, robotic automation, the Internet of Medical Things (IoMT), blockchain, DIY diagnostics, virtual care, mobility in drug delivery and clinical trials, genomics, next-generation therapies, cloud computing, Real-World Evidence (RWE), and data-driven precision medicine are the major technologies driving the life sciences sector. AI technology is being used in diagnoses, treatment planning, patient monitoring, and drug discovery. The IoMT is allowing new business models to emerge and enhancing customer experiences. Pharmaceutical companies are also increasingly using biomarkers in the drug development process to reduce the time taken to bring the product into the market. Biomarkers are biological indicators that are objectively measured and evaluated for biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention. The cold and cough preparations market is regulated by authorities such as the Food and Drug Administration in the US. For instance, the Food and Drug Administration (FDA) restricted the use of codeine in children. Codeine is approved to treat pain and cough but this medicine carries serious risks, including slowed or difficult breathing, and can be potentially fatal. This risk is greater in children younger than 12 years but the use of codeine should also be limited in some older children. Single-ingredient codeine is FDA-approved only for use in adults. FDA is also recommending against the use of codeine in breastfeeding mothers due to possible harm to their infants. Major players in the cold and cough preparation market are AstraZeneca, Bayer, Blackmores Limited, Dabur, GlaxoSmithKline, Himalaya Global Holdings, Hyland's, Johnson & Johnson, Novartis and Perrigo Company. North America was the largest region in the cold and cough preparation market in 2022. Middle East is expected to be the fastest-growing region in the global cough and cold preparations market during the forecast period. The regions covered in the global cold and cough preparation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cold and cough preparations market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The cold and cough preparations market consists of sales of dextromethorphan, guaifenesin, and phenylephrine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cough and cold preparations market is segmented - 1) By Type: Bronchodialators, Anticholinergic, Pulmonary Antihypertensives 2) By Drug Type: Antihistamines, Expectorants, Bronchodilators, Decongestants, Antibiotics, Other Types 3) By Dosage Type: Oral Syrups, Tablets/Pills, Nasal Drops, Lozenges, Other Dosage Types 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores

Drug delivery devices are used to deliver specific drugs to a specific part of the body to cure diseases. Drug delivery devices used in various patient care settings, such as hospitals, diagnostic centers, clinics, and home care settings, are included in this market. The main routes of administration of drug delivery devices is oral drug delivery, injectable drug delivery, topical drug delivery, ocular drug delivery, pulmonary drug delivery, nasal drug delivery, transmucosal drug delivery, and implantable drug delivery. Oral drug delivery is a route of drug delivery in which a tablet or capsule is administered into the alimentary canal of a human being. The patient care settings is hospitals, diagnostic centres, ambulatory surgery centres/clinics, home care settings, and others. The various applications involved are cancer, infectious diseases, respiratory diseases, diabetes, cardiovascular diseases, autoimmune diseases, central nervous system disorders, and others. The drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides drug delivery devices market statistics, including drug delivery devices industry global market size, regional shares, competitors with a drug delivery devices market share, detailed drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the drug delivery devices industry. This drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global drug delivery devices market size will grow from $81.13 billion in 2022 to $87.65 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global drug delivery devices market size is expected to grow from $115.09 billion in 2027 at a CAGR of 7.0%. The rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, cancer and other diseases is expected to drive the drug delivery devices market. According to the world health organization (WHO), by 2020, chronic diseases will account for almost three-quarters of all deaths worldwide, and 71% of deaths due to ischemic heart disease (IHD), 75% of deaths due to stroke, and 70% of deaths due to diabetes will occur in developing countries. There are various routes of drug administration for medical drugs. The selection of the route depends on three factors - the effect desired; the type of the disease and the type of the product. Currently, the development of new drug delivery systems plays a major role in the pharmaceutical industry. Research and development (R&D) in drug delivery are increasing throughout the world due to the increasing prevalence of these diseases. Most pharmaceutical companies are focusing on multiple drug delivery technologies for creating excellent advantages and better outcomes for their marketed products. Hence, the increasing prevalence of chronic diseases is resulting in increased consumption of therapeutic drugs and therapies, and this factor is expected to act as a driver for the growth of the drug delivery devices market. The regulatory changes related to medical devices is expected to restrain the growth of the drug delivery devices market. The companies operating in the market are required to adapt according to the changes in the regulatory framework, which may limit business at the bottom line. Also, companies will have to bear the heavy cost of adapting to the changing regulatory framework. Also, the sudden changes in the regulatory framework related to medical devices can result in losses, fines, and penalties at a global level. The new MDSAP will come into effect in 2020 and is adopted by regulators in the US, Canada, Japan, Brazil, and Australia. Following the changes, in Canada, all the medical device manufacturers including drug delivery products manufacturers, will have to comply with the requirements of MDSAP and are required to submit the MDSAP reports to the regulatory body in order to obtain or maintain the device licenses, resulting in high costs and time loss. Thus, the growth of the drug delivery devices market is limited by the regulatory changes related to medical devices. The microneedle (MN), is a highly efficient and versatile medical device technology, due to its prominent properties including painless penetration, low cost, excellent therapeutic efficacy, and relative safety. The major players operating in the global microneedle drug delivery system include 3M, Vetter Pharma International GmbH, nano Biosciences LLC., Nano Pass and more. The microneedles are fabricated using biodegradable polymers in which drugs or vaccines are encapsulated in the microneedles. Once, the microneedles dissolve in the skin, the drug gets released. This novel delivery method allows a wider variety of molecules to pass the skin’s barrier, thus allowing the transdermal delivery to be applied to a large range of clinical applications, including diabetes, severe osteoporosis, and influenza vaccination. Companies in the drug delivery devices market are collaborating with other companies within the industry in order to strengthen their product portfolio as well as expand their footprint across different geographies. For example, in October 2022, Nemera, a French pharmaceuticals company, partnered with Zollner Elektronik AG to develop electronic drug delivery systems. Zollner would provide its design, development, and manufacturing capabilities to help Nemera develop electronic drug delivery system. In August 2020, Sulzer, a Swiss-based engineering and manufacturing firm acquired Haselmeier GmbH for $118m. The acquisition of Haselmeier will allow Sulzer to complement its healthcare portfolio, in addition to leveraging its APS expertise in precision injection moulding to expand its presence in the drug delivery devices market. Haselmeier GmbH, a Swiss-German drug delivery device developer and manufacturer. Major players in the drug delivery devices market are F. Hoffmann-La Roche Ltd., 3M Company, Pfizer Inc., Baxter International, BD, Novartis AG, Gerresheimer AG, Johnson & Johnson Services, Inc., Bayer AG, and GlaxoSmithKline PLC. North America was the largest region in the drug delivery devices market in 2022. Asia-Pacific was the second-largest region in the global drug delivery devices market. The regions covered in the global drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the drug delivery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The drug delivery devices market consists of sales of instruments such as smart pills, inhalers and nebulizers, drug-eluting stents, safety syringes, and transdermal patches. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global drug delivery devices market is segmented - 1) By Route Of Administration: Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ocular Drug Delivery, Pulmonary Drug Delivery, Nasal Drug Delivery, Transmucosal Drug Delivery, Implantable Drug Delivery 2) By Patient Care Setting: Hospitals, Diagnostic Centers, Ambulatory Surgery Centers/Clinics, Home Care Settings, Other Patient Care Settings 3) By Application: Cancer, Infectious Diseases, Respiratory Diseases, Diabetes, Cardiovascular Diseases, Autoimmune Diseases, Central Nervous System Disorders, Other Applications

A virology specimen is a blood sample taken for examination of specimens in order to look for any type of infection.The virus isolation specimens should be collected within four days of the onset of sickness, as virus shedding reduces significantly after that. Virus cultures are not useful for specimens taken more than 7 days after the onset of sickness, with a few exceptions to be used by government health authorities, hospitals, clinicians, and laboratories that are collecting relevant clinical samples for diagnosis. The main types of virology specimen collection are blood collection kits, specimen collection tubes, viral transport media, and swabs. The vials and reagents given for use in collecting samples and transporting them to the laboratory where the testing services would be performed on such samples are referred to as the sample collection kit. Virology specimen collection samples can be blood samples, nasopharyngeal samples, throat samples, nasal samples, cervical samples, oral samples, and other samples that were taken manually or automated that can be used in diagnostic, and therapeutic. The virology specimen collection market research report is one of a series of new reports from The Business Research Company that provides virology specimen collection market statistics, including virology specimen collection industry global market size, regional shares, competitors with a virology specimen collection market share, detailed virology specimen collection market segments, market trends and opportunities, and any further data you may need to thrive in the virology specimen collection industry. This virology specimen collection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global virology specimen collection market size grew from $5.79 billion in 2022 to $6.13 billion in 2023 at a compound annual growth rate (CAGR) of 5.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The virology specimen collection market size is expected to grow to $7.2 billion in 2027 at a CAGR of 4.1%. The growing number of blood donations is driving the growth of the virology specimen collection market. With the growing number of blood samples, there is a rise in the examination and detection of viruses in the blood using the virology specimen collection method. For instance, according to WHO, a specialized agency of the United Nations responsible for international public health, in 2020, of the 118.5 million blood donations collected globally, 40% of these are collected in high-income countries, home to 16% of the world’s population. In low-income countries, up to 54 % of blood transfusions are given to children under 5 years of age, whereas, in high-income countries, over 60s are the most frequently transfused patient group, accounting for up to 75 percent of all transfusions. The blood donation rate in high-income countries is 31.5 donations per 1000 persons, 15.9 donations in upper-middle-income countries, 6.8 donations in lower-middle-income countries, and 5.0 donations in low-income countries, according to 1000-person samples. Therefore, demand for virology specimen collection is predicted to rise as the prevalence of increase in the number of blood donations. Technology development are shaping the virology specimen collection market. Technological advancements, ranging from automated sample isolation to real-time amplification technology, have enabled the development and introduction of systems for the majority of clinically relevant viruses, as well as the acquisition of clinically relevant information for optimal antiviral treatment options. For instance, in 2020, BD (Becton, Dickinson, and Company), a leading worldwide medical technology company, announced that the BD Vacutainer UltraTouchTM Push Button Blood Collection Set (BCS) with Preattached Holder has received the CE mark in Europe. The device with the preattached holder is being released in the United States under the BD Vacutainer UltraTouchTM Push Button BCS, which was previously cleared. The one-handed safety activation of the push button allows doctors to attend to the patient and venipuncture site while activating the safety mechanism. The preattached holder helps assure OSHA single-use holder compliance by protecting against inadvertent needlestick injury from the non-patient (tube-side) needle. The wing set comes as a single sterile item with a pre-assembled holder. In 2021, DiaSorin S.p.A., an India-based laboratory diagnostics market, specializing in the immunodiagnostics and molecular diagnostics segments acquired Luminex Corporation for $ 1.8 billion. With this acquisition, DiaSorin will get access to Luminex's multiplexing technology and a portfolio that will complement its current offering while also growing the Group's position in the United States as a result. This agreement will also enable access to Luminex's applications across the Life Science industry, facilitating academic and scientific research, strengthening interaction with biopharma businesses, and enhancing access to clinical multiplexing assays for future Value-Based Care projects. Luminex Corporation is a US-based developer, manufacturer, and marketer of biological testing technologies in the clinical diagnostic and life science industries. Major players in the virology specimen collection market are Puritan Medical Products Co., Becton, Dickinson and Company, Quidel Corporation, Thermo Fisher Scientific Inc., Trinity Biotech, Titan Biotech Ltd., DiaSorin SA, Vircell S.L., Copan Italia S.P.A, Hardy Diagnostics, and Laboratory Corporation of America Holdings. North America was the largest region in the virology specimen collection market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the virology specimen collection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the virology specimen collection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The virology specimen market consists of sales of conjunctiva (eye) swab, cerebral spinal fluid (csf), lesions, tissue specimens, and bone marrow. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global virology specimen collection market is segmented - 1) By Product Type: Blood Collection Kits, Specimen Collection Tubes, Viral Transport Media, Swabs 2) By Sample: Blood Samples, Nasopharyngeal Samples, Throat Samples, Nasal Sampls, Cervical Samples, Oral Samples, Other Samples 3) By Method: Manual, Automated 4) By Application: Diagnostic, Therapeutic

Mucosal atomization devices offer medication through the nostrils. It is known for providing dependable topical solution atomization across the nasal and oropharyngeal mucous membranes. The mucosal atomization devices are used to deliver atomized medication to the mucosal surfaces of the nasal, oral, and larynx, trachea, and lungs. The main types of mucosal atomization devices include nasal atomization devices, fibre-optic atomization devices, laryngotracheal atomization devices, and bottle atomizer devices. Nasal atomization devices offer a painless, safe approach to giving patients fast-acting drugs that quickly penetrate mucosal membranes and enter the bloodstream. The different mucosal atomization device technologies include gas propelled atomization devices and electrical atomization devices, which are used by end-users including hospitals, ambulatory surgical centers, and specialized clinics. The mucosal atomization devices market research report is one of a series of new reports from The Business Research Company that provides mucosal atomization devices market statistics, including mucosal atomization devices industry global market size, regional shares, competitors with an mucosal atomization devices market share, detailed mucosal atomization devices market segments, market trends and opportunities, and any further data you may need to thrive in the mucosal atomization devices industry. This mucosal atomization devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global mucosal atomization devices market size grew from $0.72 billion in 2022 to $0.78 billion in 2023 at a compound annual growth rate (CAGR) of 8.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The mucosal atomization devices market size is expected to grow to $1.07 billion in 2027 at a CAGR of 8.4%. The increase in prevalence of allergic rhinitis and sinus across the world propels the growth of the mucosal atomization devices market. Allergic rhinitis refers to a range of symptoms that affect the nose and are brought by breathing allergens such as pollen, dust, or animal dander. Sinuses refer to the hollow areas in the bones of the forehead, cheekbones, and between the eyes region and when the tissue lining the sinuses become inflamed or swollen is known as sinusitis. Mucosal atomization devices are used to provide budesonide as a topical nasal steroid spray in chronic rhinosinusitis treatment. According to the data published by ‘Sinus and Allergy Wellness Centre’, a US-based organization, in the United States, in 2020, sinusitis has impacted 300 million or 11.6% of American adults. Therefore, the increasing prevalence of allergic rhinitis and sinus across the world drives the growth of the mucosal atomization devices market. The strategic partnerships are key trends gaining popularity in the mucosal atomization devices market. Major companies operating in mucosal atomization devices are undergoing partnerships to strengthen their position in the market. For instance, in October 2021, Pulmodyne Inc., a US-based company that provides drug atomization delivery, partnered with Alcove Manufacturing and Distribution Inc., a UK-based company with this partnership, The EZ-Spray Atomization System will start to be distributed by Pulmodyne through its current channels. The cooperation aims to advance industry innovation in addition to distribution, and this connection will enable the two seasoned businesses to quickly optimize product designs. In March 2022, Kurve Technology Inc., a US-based company that engaged in the development of liquid drug delivery devices for topical, systemic, and nose-to-brain medical therapies, merged with Savile Therapeutics Inc. This merger allows Kurve Technology to gain access to the assets of Savile Therapeutics Inc and drive further growth and expansion. Savile Therapeutics Inc is a US-based medical device company. Major players in the mucosal atomization devices market are Teleflex Incorporated, DeVilbiss Healthcare LLC, Becton Dickinson and Company, Kurve Therapeutics, Cook, Medica Holdings LLC, Life-Assist Inc., MedTree (BTME Group Ltd), Integra LifeSciences, BVM Meditech Private Limited, Drive Medical, DS Medical, Wolfetory Medical Inc., MILA International, and Magal Healthcare Pvt Ltd. North America was the largest region in the mucosal atomization devices market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mucosal atomization devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the mucosal atomization devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The mucosal atomization devices market consists of sales of 3cc Syringe and VetJet. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global mucosal atomization devices market is segmented - 1) By Type: Nasal Atomization Devices, Fiber-Optic Atomization Devices, Laryngo-Tracheal Atomization Devices, Bottle Atomizer Devices 2) By Technology: Gas Propelled Atomization Devices, Electrical Atomization Devices 3) By End User: Hospitals, Ambulatory Surgical Centers, Specialized Clinics

The topical drug delivery market refers to the procedure of delivering a drug from a product on the skin to a local target site to produce a therapeutic effect. Topical drug deliveries are used to provide medication that is applied to the skin to treat different conditions. The types of products in topical drug delivery are semi-solid formulations, liquid formulations, solid formulations, and transdermal products. Semi-solid formulations refer to a group of medications referred to as semi-solids, including creams, gels, ointments, suppositories, and other unique topical dose forms. The route of administration includes dermal drug delivery, ophthalmic drug delivery, rectal drug delivery, vaginal drug delivery, and nasal drug delivery. The various end users include hospitals, clinics, home healthcare, diagnostic centers, and other end users. The topical drug delivery market research report is one of a series of new reports from The Business Research Company that provides topical drug delivery market statistics, including topical drug delivery industry global market size, regional shares, competitors with a topical drug delivery market share, detailed topical drug delivery market segments, market trends and opportunities, and any further data you may need to thrive in the topical drug delivery industry. This topical drug delivery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global topical drug delivery market size grew from $137.93 billion in 2022 to $150.69 billion in 2023 at a compound annual growth rate (CAGR) of 9.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The topical drug delivery market size is expected to grow to $210.39 billion in 2027 at a CAGR of 8.7%. The growing prevalence of diabetes is expected to propel the growth of the topical drug delivery market going forward. Diabetes is a group of diseases that affect how the body uses blood sugar and result in high blood sugar levels. Topical drug delivery helps diabetes patients by administering medicines that can bypass hepatic first-pass metabolism. For instance, in December 2021, according to the statistics published by International Diabetes Federation, a Belgium-based, non-profit diabetes association 2021, 537 million adults (20-79 years) recorded living with diabetes, and 6.7 million people died of diabetes in 2021. However, by 2030, it is anticipated that there will be 643 million people worldwide will have diabetes. Therefore, the growing prevalence of diabetes is driving the growth of the topical drug delivery market. Technological advancement is a key trend gaining popularity in the topical drug delivery market. Major companies operating in the topical drug delivery market are developing innovative products with advanced technologies to strengthen their position in the topical drug delivery market. For instance, in April 2022, Sol-Gel Technologies Ltd., an Israel-based dermatology company, and Galderma S.A., a Switzerland-based pharmaceutical company specializing in dermatological treatments and skin care products, introduced Epsolay (benzoyl peroxide, cream, 5%), utilizing Sol-Gel’s microencapsulation technology for the treatment of inflammatory lesions of rosacea, which is patent protected until 2040. Sol-gel microencapsulation provides the advantage of entrapping molecules by forming inclusion complexes between essential oils (Eos) as guest molecules and beta-cyclodextrin as host in porous silica, making it more stable and resistant to environmental conditions. Silica acts as a protector for EOs. In June 2022, Novartis AG, a Switzerland-based pharmaceutical company, acquired Kedalion Therapeutics and its AcuStream technology for an undisclosed amount. This acquisition enhances the Novartis ophthalmics portfolio, advancing efforts to investigate transformative ophthalmic methods to address unmet patient needs in front-of-eye conditions. Kedalion Therapeutics is a US-based clinical-stage, venture-funded ophthalmic drug company operating in the topical drug delivery market. Major players in the topical drug delivery market are Glenmark Pharmaceuticals Ltd., Galderma SA, Johnson & Johnson Private Limited, GlaxoSmithKline PLC., Bausch Health Companies Inc., Cipla Ltd., Bayer AG, 3M, Merck & Co., Inc., Crescita Therpeutics Inc., Novartis International AG, Taro Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International Inc., Encore Dermatology Inc., Medpharm Group Limited, SkinVisible Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co., Inc., and Pfizer Inc. North America was the largest region in the topical drug delivery market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the topical drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the topical drug delivery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The topical drug delivery market includes revenues earned by entities by lotions, gels, patches, and powders. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global topical drug delivery market is segmented - 1) By Product Type: Semi-Solid Formulations, Liquid Formulations, Solid Formulations, Transdermal Products 2) By Route Of Administration: Dermal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery, Vaginal Drug Delivery, Nasal Drug Delivery 3) By End User: Hospitals, Clinics, Home Healthcare, Diagnostic Centers, Other End Users

Peripheral vascular devices and equipment are used to treat peripheral vascular diseases which are slow and progressive blood circulation disorders caused by blockages, narrowing, or spasms in blood vessels outside the heart and brain including arteries and veins. The main types of peripheral vascular devices and equipment are peripheral vascular stents, percutaneous transluminal angioplasty balloons, catheters, PTA guide wires, atherectomy devices, chronic total Occlusion devices, aortic stents, synthetic surgical grafts, embolic protection devices, and inferior vena cava filters. The catheter is a tubular medical device for insertion into canals, vessels, passageways, or body cavities to permit injection or withdrawal of fluids or to keep a passage open. The applications involved are the treatment of peripheral blood vessels damaged and the treatment of peripheral blood vessels blockage. The various end-users are hospital applications and clinic applications. The peripheral vascular devices and equipment market research report is one of a series of new reports from The Business Research Company that provides peripheral vascular devices and equipment market statistics, including peripheral vascular devices and equipment industry global market size, regional shares, competitors with a peripheral vascular devices and equipment market share, detailed peripheral vascular devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the peripheral vascular devices and equipment industry. This peripheral vascular devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global peripheral vascular devices and equipment market size will grow from $7.77 billion in 2022 to $8.27 billion in 2023 at a compound annual growth rate (CAGR) of 6.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The peripheral vascular devices and equipment market size is expected to grow to $10.04 billion in 2027 at a CAGR of 5.0%. The peripheral vascular devices and equipment market is driven by the rising number of people with peripheral artery diseases. Peripheral artery diseases are caused when arteries in the human body are blocked by plaque consisting of fats, cholesterol, and other substances restricting their blood flow to important organs. Lower extremity peripheral artery disease (PAD) affects >230 million adults worldwide and is associated with increased risk of various adverse clinical outcomes (other cardiovascular diseases such as coronary heart disease and stroke and leg outcomes such as amputation. The disease is different in younger populations; but, the incidence rises sharply, with over 20% of people over 80 years old having PAD. According to the Center for Disease Control and Prevention (CDC), approximately 8.5 million people in the USA are suffering from peripheral artery diseases, of which 12-20% are aged above 60 years. Stringent approval processes, product recalls and failures act as a restraint to the peripheral vascular devices and equipment market. Product recalls and failures potentially affect the brand image of the companies within this market. According to the US Food and Drug Administration (FDA), a product recall is made to perform corrective actions or prevent hazardous effects to patients. For instance, in January 2022, Medtronic was instructed to recall its artery-clearing HawkOne System due to reported injuries. \ To reduce incidences associated with the peripheral devices and ensure that the devices are safe and have the least adverse reactions, FDA is restricting devices for use, sending field safety notices, and making product recall to correct the devices. These stringent approval processes and regulatory policies may impact the peripheral devices and equipment market. Bio-absorbable stents are gaining popularity in the peripheral vascular devices and equipment market to eliminate thrombogenic risk factors and enhance clinical applicability. Bio-absorbable stents are made of natural soluble materials that disappear after insertion and eliminate the risk of late stent thrombosis. They help in protecting the body from inflammation or reduced blood flow due to late-stent thrombosis (a condition where the stent used for treatment stays inside the body for a prolonged period). Companies in this market are increasing their focus on developing and commercializing bio-absorbable stents. For instance, in 2020, Boston Scientific is demanded to start its Synergy Megatron bioabsorbable polymer coronary stent system. It is intended for large proximal vessels, including over main, bifurcations, and ostial lesions. It is made in 3.5 mm to 5.0 mm diameters. It owns enhanced strength and the capacity to create tapered vessels. In January 2022, the U.S Food and Drug Administration issued notice to Medtronic plc for Class I medical device recall for its HawkOne System for clearing out clogged arteries. The notice was issue after certain instances of injuries were reported. In September 2021, Boston Scientific, a US-based manufacturer of medical devices acquired Devoro Medical, Inc for an undisclosed amount. This acquisition of devoro medical inc will add the WOLF platform and advances efforts to ensure physicians have the right tools to improve procedural efficiencies. Devoro Medical, Inc., is a US-based manufacturer of medical technology. Major players in the peripheral vascular devices and equipment market are Medtronic, Boston Scientific Corporation, Abbott, Cook group, Angiomed GmbH & Co., Medizintechnik KG, Terumo Corporation, ENDOLOGIX Inc., Bolton medical Inc., and JOTEC. North America was the largest region in global peripheral vascular devices and equipment market in 2022. Western Europe was the second-largest region in global peripheral vascular devices and equipment market. The regions covered in the peripheral vascular devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the peripheral vascular devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, and Australia. The peripheral vascular devices and equipment market consist of sales of peripheral vascular stents, percutaneous transluminal angioplasty balloons, PTA drug-eluting balloons, embolic protection devices, inferior vena cava filters, Aortic stent-grafts, synthetic surgical drafts, and peripheral guide wires. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global peripheral vascular devices and equipment market is segmented - 1) By Type: Peripheral vascular stents, Percutaneous transluminal angioplasty balloons, Catheters, PTA guide wires, Atherectomy devices, Chronic total acclusion devices, Aortic stents, Synthetic surgical grafts, Embolic protection devices, Inferior vena cava filters 2) By End User: Hospital applications, Clinic applications, 3) By Application: Treatment of Peripheral Blood Vessels Damaged, Treatment of Peripheral Blood Vessels Blockage